ABOS
Acumen Pharmaceuticals Inc
2.10$
+1.9%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -33.2% | +383.4% | -54.9% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | -6.0% | +55.4% | -65.7% | +146.7% | -10.9% | -20.1% | +215.2% | +5.5% | +22.3% | +13.5% | +29.3% | -18.9% | +4.8% | -94.8% | -91.8% | +12.8% | +2.3% | +0.0% | -2.2% | +2.3% | – | – | – | +2.2% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -6.0% | +55.4% | -65.7% | +151.3% | -12.6% | -20.1% | +215.2% | +5.5% | +22.3% | +13.5% | +29.3% | -18.9% | +4.8% | +22.4% | +18.9% | -6.3% | +56.9% | +39.5% | +26.9% | -26.9% | +46.9% | -40.8% | -6.6% | -19.7% | +68.7% | – | |
| – | +16.7% | -12.7% | +185.0% | +88.7% | -2.3% | +79.9% | +28.4% | +17.5% | -4.1% | -0.9% | +14.4% | +26.3% | -1.7% | +11.9% | +6.9% | +2.5% | -9.0% | +3.5% | +0.2% | +1.5% | -9.4% | -1.7% | +2.8% | -0.2% | +1.8% | – | |
| – | +16.7% | -12.7% | +185.0% | +489.0% | -68.7% | +79.9% | +28.4% | +17.5% | -4.1% | -0.9% | +14.4% | +26.3% | -1.7% | +258.3% | +18.5% | -3.6% | +37.2% | +32.3% | +22.6% | -23.2% | +37.5% | -36.5% | -5.0% | -16.3% | +54.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | +187.0% | +15.2% | +242.1% | +155.0% | -27.8% | +281.6% | +3.1% | -100.0% | – | +72.1% | +0.4% | +2.3% | +1.0% | -1.4% | +2.2% | +2.1% | +1.8% | -1.7% | +2.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | +149.6% | -100.1% | – | – | – | – | – | -283.2% | – | – | – | -101.2% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -203,600.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.